{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:44:14Z","timestamp":1793198654152,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2023-PT320\\u201302"],"award-info":[{"award-number":["2023-PT320\\u201302"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LHDMY22H160007"],"award-info":[{"award-number":["LHDMY22H160007"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY21H160019"],"award-info":[{"award-number":["LY21H160019"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017287","name":"Special Funds for the Basic Research and Development Program in the Central Non-profit Research Institutes of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203240"],"award-info":[{"award-number":["82203240"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902410"],"award-info":[{"award-number":["81902410"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.critrevonc.2025.104784","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:14:09Z","timestamp":1748430849000},"page":"104784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Advances in improving the efficacy of anti-PD-1\/PD-L1 therapy in intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"213","author":[{"given":"Shanhe","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenguang","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104784_bib1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations","volume":"39","author":"Affo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104784_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/ijms25010461","article-title":"Molecular Profile of Intrahepatic Cholangiocarcinoma","volume":"25","author":"Andraus","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.critrevonc.2025.104784_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41571-021-00560-7","article-title":"Predicting cancer outcomes with radiomics and artificial intelligence in radiology","volume":"19","author":"Bera","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba2609","article-title":"Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade","volume":"372","author":"Berry","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104784_bib6","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/2159-8290.CD-21-0090","article-title":"Artificial Intelligence in Cancer Research and Precision Medicine","volume":"11","author":"Bhinder","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104784_bib7","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2025.104784_bib8","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-24-0517","article-title":"FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer","volume":"30","author":"Casak","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104784_bib9","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.104784_bib10","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.3390\/cancers13092184","article-title":"Natural Killer\u2013Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy","volume":"13","author":"Cazzetta","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104784_bib11","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1007\/s00262-023-03523-2","article-title":"Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis","volume":"72","author":"Chao","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104784_bib12","article-title":"Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+\u2009T cell exhaustion and anti-PD-1 resistance","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2025.104784_bib13","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2326-6066.CIR-23-0486","article-title":"Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti\u2013PD-1 Therapy","volume":"12","author":"Chen","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.104784_bib14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1186\/s12967-023-04804-1","article-title":"ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2025.104784_bib15","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-21-1157","article-title":"Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma","volume":"28","author":"Chen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104784_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000530273","article-title":"Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor","volume":"12","author":"Cheng","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.critrevonc.2025.104784_bib17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/hep4.1682","article-title":"Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell\u2013Mediated Antitumor Immunity Through PD-L1","volume":"6","author":"Chui","year":"2022","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.critrevonc.2025.104784_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010173","article-title":"Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma","volume":"13","author":"Chung","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104784_bib19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104784_bib20","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1016\/j.molcel.2021.07.003","article-title":"N7-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression","volume":"81","author":"Dai","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2025.104784_bib21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2020.11.037","article-title":"CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma","volume":"74","author":"Diggs","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib22","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2021.10.030","article-title":"Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma","volume":"76","author":"Ding","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104784_bib24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrc3611","article-title":"Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms","volume":"13","author":"Elinav","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104784_bib25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41419-023-06406-7","article-title":"The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations","volume":"15","author":"Feng","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2025.104784_bib26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104784_bib27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12967-024-05529-5","article-title":"Identification and validation of inflammatory subtypes in intrahepatic cholangiocellular carcinoma","volume":"22","author":"Gao","year":"2024","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2025.104784_bib28","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1158\/2159-8290.CD-21-0764","article-title":"Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic","volume":"11","author":"Grover","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104784_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113337","article-title":"Response to programmed cell death protein 1 antibody in patients with Epstein\u2013Barr virus-associated intrahepatic cholangiocarcinoma","volume":"194","author":"He","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104784_bib30","article-title":"Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma","author":"Hong","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2025.104784_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib32","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jhep.2020.10.037","article-title":"Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma","volume":"74","author":"Huang","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2025.104784_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71974-3","article-title":"High levels of tumor cell-intrinsic STING signaling are associated with increased infiltration of CD8+\u2009T cells in dMMR\/MSI-H gastric cancer","volume":"14","author":"Kanoda","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104784_bib35","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104784_bib36","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/liv.14814","article-title":"Implication of CD69+ CD103+ tissue-resident-like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma","volume":"41","author":"Kim","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.critrevonc.2025.104784_bib37","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-022-05443-0","article-title":"Ferroptosis of tumour neutrophils causes immune suppression in cancer","volume":"612","author":"Kim","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104784_bib38","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib39","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.21037\/tlcr-24-552","article-title":"Emerging insights into STK11, KEAP1 and KRAS mutations: implications for immunotherapy in patients with advanced non-small cell lung cancer","volume":"13","author":"Knetki-Wr\u00f3blewska","year":"2024","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104784_bib40","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1038\/s41467-022-31535-6","article-title":"Network-based machine learning approach to predict immunotherapy response in cancer patients","volume":"13","author":"Kong","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104784_bib41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41416-021-01569-6","article-title":"Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma","volume":"126","author":"Lan","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104784_bib42","article-title":"Case report: Immunotherapy plus chemotherapy and stereotactic ablative radiotherapy (ICSABR): a novel treatment combination for Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104784_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41525-021-00249-x","article-title":"Immune cell infiltration signatures identified molecular subtypes and underlying mechanisms in gastric cancer","volume":"6","author":"Lin","year":"2021","journal-title":"npj Genom. Med."},{"key":"10.1016\/j.critrevonc.2025.104784_bib44","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gutjnl-2022-327230","article-title":"Targeting tumour-intrinsic N7 -methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy","volume":"72","author":"Liu","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.critrevonc.2025.104784_bib45","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.7150\/thno.36276","article-title":"Distinct PD-L1\/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors","volume":"9","author":"Lu","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2025.104784_bib46","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.32387","article-title":"Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression","volume":"76","author":"Luo","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2025.104784_bib47","article-title":"Immunotherapy: Reshape the Tumor Immune Microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib48","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathmechdis-032221-115501","article-title":"Innate Immunity and Cancer Pathophysiology","volume":"17","author":"Maiorino","year":"2022","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.critrevonc.2025.104784_bib50","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","article-title":"Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications","volume":"72","author":"Martin-Serrano","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.critrevonc.2025.104784_bib51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12072-022-10445-1","article-title":"The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion","volume":"17","author":"Meng","year":"2023","journal-title":"Hepatol. Int"},{"key":"10.1016\/j.critrevonc.2025.104784_bib52","unstructured":"National Comprehensive Cancer Network, Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Biliary Tract Cancers Version 1.2025. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"key":"10.1016\/j.critrevonc.2025.104784_bib53","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2025.104784_bib54","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE -158 and KEYNOTE -028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104784_bib55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumour-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.semcancer.2022.04.004","article-title":"Inflammation targeted nanomedicines: Patents and applications in cancer therapy","volume":"86","author":"Praveen","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib57","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-21-0468","article-title":"M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma","volume":"81","author":"Qiu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104784_bib58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2025.104784_bib59","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/cncr.34394","article-title":"A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT -01","volume":"128","author":"Sahai","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104784_bib60","article-title":"BilT03: Phase 1b\/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer","author":"Sahai","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.critrevonc.2025.104784_bib61","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Sig Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.104784_bib62","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.3748\/wjg.v21.i12.3472","article-title":"Lessons from rare tumors: Hepatic lymphoepithelioma-like carcinomas","volume":"21","author":"Solinas","year":"2015","journal-title":"WJG"},{"key":"10.1016\/j.critrevonc.2025.104784_bib63","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1158\/1078-0432.CCR-22-1244","article-title":"FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures","volume":"28","author":"Sridharan","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104784_bib64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s40425-019-0596-y","article-title":"Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade","volume":"7","author":"Sui","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104784_bib65","article-title":"Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110349","article-title":"PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-\u03b2 receptor I versus II","volume":"38","author":"Sun","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2025.104784_bib67","article-title":"Abnormal metabolism in hepatic stellate cells: Pandora\u2019s box of MAFLD related hepatocellular carcinoma","volume":"1879","author":"Sun","year":"2024","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104784_bib68","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/liv.15366","article-title":"KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression","volume":"42","author":"Tanaka","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.critrevonc.2025.104784_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103919","article-title":"Phase I\/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808\/NCCH1817, SNIPE)","volume":"9","author":"Ueno","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104784_bib70","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104784_bib71","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1007\/s11605-019-04111-5","article-title":"Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery","volume":"23","author":"Vigano","year":"2019","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.critrevonc.2025.104784_bib72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.102460","article-title":"Body Composition in Cholangiocarcinoma Affects Immune Cell Populations in the Tumor and Normal Liver Parenchyma","volume":"15","author":"Wang","year":"2025","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib74","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12967-020-02437-2","article-title":"Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience","volume":"18","author":"Wang","year":"2020","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2025.104784_bib75","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.7150\/jca.74275","article-title":"Evaluating prognostic value of biliary stone in intrahepatic cholangiocarcinoma by propensity score matching analysis","volume":"14","author":"Wang","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104784_bib76","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 Blockade in Cancer Immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.critrevonc.2025.104784_bib77","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-022-01253-z","article-title":"Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses","volume":"15","author":"Xia","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202101230","article-title":"IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma","volume":"8","author":"Xiang","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2025.104784_bib79","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.ccell.2024.08.013","article-title":"Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer","volume":"42","author":"Xu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104784_bib80","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2024.03.016","article-title":"FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma","volume":"81","author":"Xu","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib81","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13046-021-02095-2","article-title":"circHMGCS1\u2013016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma","volume":"40","author":"Xu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104784_bib82","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12967-022-03342-6","article-title":"SIRP\u03b1 and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma","volume":"20","author":"Yang","year":"2022","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2025.104784_bib83","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12916-024-03257-7","article-title":"Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma","volume":"22","author":"Yang","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.critrevonc.2025.104784_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109687","article-title":"Levels of pretreatment serum lipids predict responses to PD-1 inhibitor treatment in advanced intrahepatic cholangiocarcinoma","volume":"115","author":"Yang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib85","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.2147\/JIR.S385921","article-title":"Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma","volume":"15","author":"Yang","year":"2022","journal-title":"JIR"},{"key":"10.1016\/j.critrevonc.2025.104784_bib86","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1038\/s41598-021-85186-6","article-title":"Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status","volume":"11","author":"Yugawa","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104784_bib87","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/2159-8290.CD-23-0282","article-title":"An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS -Mutant Intrahepatic Cholangiocarcinoma","volume":"13","author":"Zhang","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104784_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.101954","article-title":"Identification of clinically relevant subsets CD39+PD-1+CD8+\u2009T cells and CD39+\u2009regulatory T cells in intrahepatic cholangiocarcinoma using single-cell CyTOF","volume":"44","author":"Zhang","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib89","article-title":"Low expression and Hypermethylation of ATP2B1 in Intrahepatic Cholangiocarcinoma Correlated With Cold Tumor Microenvironment","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104784_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104784_bib91","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13513","article-title":"High endothelial venule is a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma","volume":"56","author":"Zhou","year":"2023","journal-title":"Cell Prolif."},{"key":"10.1016\/j.critrevonc.2025.104784_bib92","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s00262-023-03466-8","article-title":"Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study","volume":"72","author":"Zhu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104784_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101168","article-title":"Targeted genomic profiling revealed a unique clinical phenotype in intrahepatic cholangiocarcinoma with fibroblast growth factor receptor rearrangement","volume":"14","author":"Zhu","year":"2021","journal-title":"Transl. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:24:03Z","timestamp":1778581443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":93,"alternative-id":["S1040842825001726"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104784","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in improving the efficacy of anti-PD-1\/PD-L1 therapy in intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104784"}}